| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-12-23 | Newron Pharmaceuticals (Italy) | nomination |
Nomination | |||
| 2016-12-22 | Isis Pharmaceuticals (USA - CA) - Janssen Biotech, a J&J company (USA - NJ) | antisense drugs | autoimmune disorders of the gastrointestinal (GI) tract | R&D |
Autoimmune diseases - Gastrointestinal diseases - Digestive diseases | Milestone |
| 2016-12-22 | Sun Pharmaceutical Industries (India) Moebius Medical (Israel) | MM-II | pain in osteoarthritis | licensing | Inflammatory diseases - Rheumatic diseases | Licensing agreement |
| 2016-12-22 | Sun Pharmaceutical Industries (India) Novartis (Switzerland) | Odomzo® (sonidegib - LDE225) | adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. | product acquisition | Cancer - Oncology | Product acquisition |
| 2016-12-21 | Paion (Germany) Yichang Humanwell Pharmaceutical (China) | remimazolam | sedation | licensing - development - manufacturing - production - commercialisation | CNS diseases | Licensing agreement |
| 2016-12-21 | Exelixis (USA - CA) Ipsen (France) | cabozantinib | advanced renal cell carcinoma | development licensing commercialisation |
Cancer - Oncology | Licensing agreement |
| 2016-12-21 | Takeda Pharmaceutical (Japan) Tigenix (Belgium) | Cx601 (adipose derived allogeneic stem cell therapy) | complex perianal fistulas in patients with Crohn's disease | licensing development commercialisation |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Exercise of an option agreement |
| 2016-12-21 | Bayer Healthcare (Germany) Leica Biosystems (Germany) | companion diagnostic tests for cancer patients | development |
Cancer - Oncology | Development agreement | |
| 2016-12-21 | Amag Pharmaceuticals (USA - MA) | nomination | Nomination | |||
| 2016-12-21 | BioInvent (Sweden) Pfizer (USA - NY) | five antibodies targeting tumour-associated myeloid cells | research - licensing | Cancer - Oncology | Licensing agreement | |
| 2016-12-20 | Soligenix (USA - NJ) IDT Biologika (Germany) | production technology for the RiVax™ vaccine | collaboration manufacturing bioproduction |
Rare diseases | Collaboration agreement | |
| 2016-12-20 | Akebia Therapeutics (USA - MA) Otsuka Pharmaceuticals (Japan) | vadadustat | anemia associated with chronic kidney disease (CKD) | development commericalisation |
Kidney diseases - Renal diseases | Development agreement |
| 2016-12-20 | BMS (USA - NY) PsiOxus Therapeutics (UK) | NG-348 | solid tumors | licensing |
Cancer - Oncology | Licensing agreement |
| 2016-12-20 | Lion Biotechnologies (USA - CA) H. Lee Moffitt Cancer Center and Research Institute (USA - Fl) | nivolumab and TIL (tumor infiltrating lymphocyte) therapy | metastatic melanoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2016-12-19 | AstraZeneca (UK) Ionis Pharmaceuticals (USA - CA) | antisense therapies for cardiovascular, metabolic and renal diseases | cardiovascular diseases, metabolic diseases, renal diseases | collaboration |
Cardiovascular diseases - Metabolic diseases - Renal diseases | Milestone |
| 2016-12-19 | CytRx Corporation (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-12-19 | Innate Pharma (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-12-19 | Biogen (USA - MA) | nomination |
Nomination | |||
| 2016-12-19 | Adaptimmune (UK) Bellicum Pharmaceuticals (USA - TX) | T-cell therapies | development, commercialisation | Cancer - Oncology | Development agreement | |
| 2016-12-19 | Catalyst Biosciences (USA - CA) Pfizer (USA - NY) | marzeptacog alfa activated (CB 813d) | hemophilia A with inhibitors, hemophilia B with inhibitors | manufacturing - bioproduction | Rare diseases - Genetic diseases - Hematological diseases | Production agreement |
